Viewing Study NCT06816992


Ignite Creation Date: 2025-12-24 @ 3:15 PM
Ignite Modification Date: 2025-12-24 @ 3:15 PM
Study NCT ID: NCT06816992
Status: RECRUITING
Last Update Posted: 2025-03-20
First Post: 2025-02-03
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC
Sponsor: ORIC Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module